Application note

Application note: Droplet Digital polymerase chain reaction (ddPCR) is well suited for quantifying transgene copy number

This application note discusses why CAR T-cell therapy is so exciting, notes some common hurdles in development and manufacturing and proposes ddPCR technology as a solution for some of these issues.

Since they entered clinics in 2017, chimeric antigen receptor (CAR) T cells have transformed leukaemia and lymphoma treatment. The US Food and Drug Administration (FDA) has approved five CAR T-cell therapies so far and because most cell immunotherapies currently in development utilise CAR T cells, the number of therapeutic options is set to increase. One forecast predicts that the CAR T-cell market will grow to be worth $6.1 billion by 2030.